Company Profile
IDEAYA Biosciences Stock Price, News & Analysis
- Ticker:
- IDYA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
36.24 USD (+0.55%)
Close
Last updated: August 6, 2026
2.45B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IDYA closed up 0.55% at $36.24. No new same-company headline was identified in the current news window.
Company overview
Precision Oncology Portfolio
IDEAYA Biosciences develops targeted oncology therapies using synthetic lethality and biomarker-defined patient selection. Its portfolio combines a late-stage uveal melanoma franchise with antibody-drug conjugates and small molecules directed at genetically defined cancers.
Darovasertib in Metastatic Uveal Melanoma
Darovasertib is a protein kinase C inhibitor being developed with crizotinib. The Phase 2/3 OptimUM-02 trial met its primary endpoint in first-line HLA-A2-negative metastatic uveal melanoma and supports a planned accelerated-approval NDA.
Broader Uveal Melanoma Development
OptimUM-01 evaluates the darovasertib combination in HLA-A2-positive metastatic disease, while OptimUM-09 studies neoadjuvant treatment in primary uveal melanoma. IDEAYA is also planning the Phase 3 OptimUM-11 trial in the adjuvant setting.
ADC Pipeline
IDE849 is a DLL3-targeted topoisomerase-1 antibody-drug conjugate in Phase 1/2 development, with a registrational monotherapy trial planned in DLL3-positive tumors. IDE034 is a bispecific B7H3 and PTK7 topoisomerase-1 ADC in early clinical development.
Synthetic-Lethality Combinations
IDE397 inhibits MAT2A in MTAP-deleted tumors, while IDE892 targets PRMT5. A planned combination cohort will test dual suppression of the methylthioadenosine pathway in biomarker-selected cancers.
Future catalysts
Complete OptimUM-02 data in a late-breaking oral presentation at ASCO 2026.
Completion of the darovasertib NDA filing targeted for the second half of 2026.
Clinical updates from OptimUM-01, OptimUM-09, IDE849 and IDE034 expected in the second half of 2026.
Initiation of the IDE892-plus-IDE397 Phase 1 combination cohort planned for mid-2026.
Initiation of a registrational IDE849 monotherapy trial planned by year-end 2026.
Recent news
- 01
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Source: IDEAYA Biosciences
- 02
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Source: IDEAYA Biosciences
- 03
- 04
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
Source: IDEAYA Biosciences
- 05
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
Source: IDEAYA Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of IDEAYA Biosciences (IDYA)?
IDEAYA Biosciences (IDYA) most recently closed at 36.24 USD, a +0.55% move versus the previous session.
What is the market cap of IDEAYA Biosciences (IDYA)?
IDEAYA Biosciences currently has a market capitalization of 2.45B USD on BioPharmSignal.
What does IDEAYA Biosciences do?
Precision Oncology Portfolio IDEAYA Biosciences develops targeted oncology therapies using synthetic lethality and biomarker-defined patient selection. Its portfolio combines a late-stage uveal melanoma franchise with antibody-drug conjugates and small molecules directed at genetically defined cancers. Darovasertib in Metastatic Uveal Melanoma Darovasertib...
On which exchange is IDYA stock listed?
IDEAYA Biosciences (IDYA) is associated with NASDAQ, United States, Biopharma.
What is HLA-A2?
The Phase 2/3 OptimUM-02 trial met its primary endpoint in first-line HLA-A2-negative metastatic uveal melanoma and supports a planned accelerated-approval NDA.
Which conditions is IDEAYA Biosciences targeting with HLA-A2?
IDEAYA Biosciences is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does IDEAYA Biosciences describe recent progress with HLA-A2?
Complete OptimUM-02 data in a late-breaking oral presentation at ASCO 2026. Completion of the darovasertib NDA filing targeted for the second half of 2026. Clinical updates from OptimUM-01, OptimUM-09, IDE849 and IDE034 expected in the second half of 2026. Initiation of the IDE892-plus-IDE397 Phase 1 combination cohort planned for mid-2026. Initiation of a...
What is crizotinib?
Darovasertib in Metastatic Uveal Melanoma Darovasertib is a protein kinase C inhibitor being developed with crizotinib.